Fusion Antibodies is a Belfast based, revenue generating and profitable CRO providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's mission is to enable biopharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Clients of the Company have a number of new drugs, which the Company has been involved in the development of through antibody humanisation, which have entered or are proposed to be entering clinical trials.

The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011.

The Company provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using the Company's proprietary CDRx™ platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its clients.

The Company has an international, blue-chip client base, which includes eight of the top ten global pharmaceutical companies by revenue. A significant amount of the Company's revenue is generated from follow on service requests from existing clients, providing good visibility of future earnings.

The Company's growth strategy is based on the expansion of its client base as well as the addition of new services including antibody affinity maturation and development of a mammalian antibody library. This strategy uses the Company's proven technology and expertise and targets expansion both in the UK market and internationally.